F. Locatelli et al., Factors associated with outcome after cord blood transplantation in children with acute leukemia, BLOOD, 93(11), 1999, pp. 3662-3671
We have analyzed factors influencing the outcome of 102 children with acute
leukemia given a cord blood transplantation (CBT) and reported to the Euro
cord Registry. Seventy patients with acute lymphoblastic and 32 with acute
myeloid leukemia were given either a related (n = 42) or an unrelated (n =
60) CBT. Children given CBT during first or second complete remission were
considered as belonging to the good-risk group (n = 66), whereas those who
received a transplant in a more advanced stage of disease were assigned to
the poor-risk group (n = 36). In the related group (RCBT), 12 of 42 patient
s received transplantation from an HLA-disparate donor, whereas in the unre
lated group (UCBT) 54 of 60 received an HLA mismatched CBT Kaplan-Meier est
imates for neutrophil recovery at day 60 were 84% +/- 7% in RCBT and 79 +/-
6% in UCBT (P=.16). In multivariate analysis, the most important factor in
fluencing neutrophil engraftment in UCBT was a nucleated cell dose infused
greater than 3.7 x 10(7)/kg (P =.05, relative risk [RR] of 1.85, 95% confid
ence interval [CII: 0.98-3.4). The incidence of grade II through IV acute g
raft-versus-host disease was 41% +/- 8% in the RCBT group and 37% +/- 6% In
the UCBT group (P =.59). Kaplan-Meier estimates of 2-year event-free survi
val (EFS) after RCBT or UCBT were 39% +/- 8% and 30% +/- 7%, respectively (
P=.19). In multivariate analysis, the most important factor influencing EFS
was disease status at time of transplantation: good-risk patients had a 2-
year EFS of 49% +/- 7% as compared to 8% +/- 5% in patients with more advan
ced disease (P =.0003, RR: 0.40, 95% CI: 0.24 to 0.65). This was a conseque
nce of both an increased 1-year transplant related mortality and a higher 2
-year relapse rate in the poor-risk group (65% +/- 9% and 77% +/- 14%, resp
ectively), as compared with good risk patients (34% +/- 6% and 31% +/- 9%,
respectively). These data confirm that allogeneic CBT from either a related
or an unrelated donor is a feasible procedure able to cure a significant p
roportion of children with acute leukemia, especially if transplanted in a
favorable phase of disease. (C) 1999 by The American Society of Hematology.